Tuesday July 28, 2026 | EN FR AR Live

HIV

Long-Running South African Study Reveals Persistent HIV Immune Activity in the Brain Despite Blood Viral Suppression

Long-Running South African Study Reveals Persistent HIV Immune Activity in the Brain Despite Blood Viral Suppression

Researchers tracking a cohort of South African adolescents over sixteen years have reported finding persistent HIV-specific immune activity in the central nervous system, even in participants whose viral loads are fully suppressed in the bloodstream. The finding, discussed at a scientific meeting in Rio de Janeiro, Brazil, challenges the long-held assumption that suppressing HIV in […]

Long-Running South African Study Reveals Persistent HIV Immune Activity in the Brain Despite Blood Viral Suppression Read More »

U.S. Defends New HIV Funding Model as Activists Challenge PEPFAR Reforms at AIDS 2026

U.S. Defends New HIV Funding Model as Activists Challenge PEPFAR Reforms at AIDS 2026

HIV activists confronted senior U.S. officials on the eve of the AIDS 2026 international conference in Rio de Janeiro, voicing alarm over sweeping reforms to Washington’s flagship global AIDS programme and accusing the Trump administration of triggering a public health emergency through funding cuts. The exchanges, which took place ahead of the formal opening of

U.S. Defends New HIV Funding Model as Activists Challenge PEPFAR Reforms at AIDS 2026 Read More »

Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results in Africa

Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results in Africa

A long-acting injectable drug, lenacapavir, administered just twice a year, continues to demonstrate strong protection against HIV infection in ongoing studies across Africa, according to recent reports. The development marks a significant step forward in the global effort to expand prevention options for populations at risk of contracting the virus. A New Approach to HIV

Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results in Africa Read More »

New Evidence Highlights Widespread Disruptions to PEPFAR-Funded HIV Services Across Africa

New Evidence Highlights Widespread Disruptions to PEPFAR-Funded HIV Services Across Africa

The first large-scale assessment by organisations implementing the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) indicates that recent shifts in funding and policy have triggered widespread interruptions to HIV services across Africa, with local organisations, children and key populations among those most severely affected. PEPFAR, launched in the early 2000s, has long been one

New Evidence Highlights Widespread Disruptions to PEPFAR-Funded HIV Services Across Africa Read More »

Rwanda Maintains Low Mother-to-Child HIV Transmission Rate, Latest Health Report Shows

Rwanda Maintains Low Mother-to-Child HIV Transmission Rate, Latest Health Report Shows

Rwanda has maintained a mother-to-child HIV transmission rate below 2 percent over the past decade, even as the figure edged up slightly in the most recent reporting period, according to the Rwanda Biomedical Centre (RBC) HIV, STIs, and Viral Hepatitis Annual Report 2024/2025. The report, published by the state-run institution that coordinates the country’s response

Rwanda Maintains Low Mother-to-Child HIV Transmission Rate, Latest Health Report Shows Read More »

US to end funding for HIV programmes in South Africa, raising concerns over treatment gaps

US to end funding for HIV programmes in South Africa, raising concerns over treatment gaps

The United States has announced it will stop funding HIV programmes in South Africa, a decision that has raised concerns among health experts and advocacy groups in the country with the world’s largest HIV-positive population. More than eight million South Africans are living with the virus, according to widely cited estimates, making the country the

US to end funding for HIV programmes in South Africa, raising concerns over treatment gaps Read More »